City Therapeutics, Inc. (NASDAQ:CTY) Stock Has Consensus Price Target of $37.33

City Therapeutics, Inc. (NASDAQ:CTY) has been given a consensus recommendation of “Moderate Buy” by the four ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $37.33.

CTY has been the topic of a number of analyst reports. Jefferies Financial Group assumed coverage on City Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $32.00 price target on the stock. Oppenheimer started coverage on City Therapeutics in a report on Tuesday. They set an “outperform” rating and a $46.00 price objective for the company. Wall Street Zen upgraded shares of City Therapeutics to a “hold” rating in a research note on Saturday, October 24th. Stifel Nicolaus initiated coverage on shares of City Therapeutics in a research report on Tuesday. They set a “buy” rating and a $34.00 target price for the company. Finally, Zacks Research started coverage on shares of City Therapeutics in a research report on Wednesday. They set a “hold” rating for the company.

City Therapeutics Stock Performance

NASDAQ:CTY opened at $18.98 on Friday. City Therapeutics has a 52-week low of $15.81 and a 52-week high of $23.88.

Insider Buying and Selling

In other City Therapeutics news, Director Robert Nelsen bought 170,000 shares of the stock in a transaction on Monday, October 19th. The stock was purchased at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the acquisition, the director owned 13,692,507 shares of the company’s stock, valued at approximately $246,465,126. The trade was a 1.26% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Arch Venture Partners Xii, Llc acquired 170,000 shares of the company’s stock in a transaction that occurred on Monday, October 19th. The stock was bought at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the acquisition, the insider directly owned 13,692,507 shares of the company’s stock, valued at $246,465,126. The trade was a 1.26% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

About City Therapeutics

City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.